Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Walsh

Showing results (1171-1180 of 1,300) with videos related to

Pageof 130
Sort By:
Nature|March 27, 2012
IFITM3 restricts the morbidity and mortality associated with influenzaAaron R Everitt, Simon Clare, Thomas Pertel, et al.
Vaccine|September 10, 2009
Recombinant Liver Stage Antigen-1 (LSA-1) formulated with AS01 or AS02 is safe, elicits high titer antibody and induces IFN-gamma/IL-2 CD4+ T cells but does not protect against experimental Plasmodium falciparum infectionJames F Cummings, Michele D Spring, Robert J Schwenk, et al.
JAMA|May 19, 2025
Dexmedetomidine- or Clonidine-Based Sedation Compared With Propofol in Critically Ill Patients: The A2B Randomized Clinical TrialTimothy S Walsh, Richard A Parker, Leanne M Aitken, et al.
Thorax|October 10, 2014
Diagnostic accuracy of pulmonary host inflammatory mediators in the exclusion of ventilator-acquired pneumoniaThomas P Hellyer, Andrew Conway Morris, Daniel F McAuley, et al.
Neuro-Oncology|July 5, 2022
MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensusPeter M K de Blank, Andrea M Gross, Srivandana Akshintala, et al.
Neurology|December 14, 2016
Randomized placebo-controlled study of lovastatin in children with neurofibromatosis type 1Jonathan M Payne, Belinda Barton, Nicole J Ullrich, et al.
JAMA|December 9, 2024
Biomarker-Guided Antibiotic Duration for Hospitalized Patients With Suspected Sepsis: The ADAPT-Sepsis Randomized Clinical TrialPaul Dark, Anower Hossain, Daniel F McAuley, et al.
Journal of Medicinal Chemistry|May 31, 2002
3-Aminopyrrolidinone farnesyltransferase inhibitors: design of macrocyclic compounds with improved pharmacokinetics and excellent cell potencyIan M Bell, Steven N Gallicchio, Marc Abrams, et al.
American Journal of Respiratory and Critical Care Medicine|August 16, 2022
An Inhaled Galectin-3 Inhibitor in COVID-19 Pneumonitis: A Phase Ib/IIa Randomized Controlled Clinical Trial (DEFINE)Erin E Gaughan, Tom M Quinn, Andrew Mills, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|March 25, 2014
Development of a liver-targeted siRNA delivery platform with a broad therapeutic window utilizing biodegradable polypeptide-based polymer conjugatesStephanie E Barrett, Rob S Burke, Marc T Abrams, et al.
Pageof 130

Showing results (1171-1180 of 1,300) with videos related to

Sort By:
Pageof 130
Nature|March 27, 2012
IFITM3 restricts the morbidity and mortality associated with influenzaAaron R Everitt, Simon Clare, Thomas Pertel, et al.
Vaccine|September 10, 2009
Recombinant Liver Stage Antigen-1 (LSA-1) formulated with AS01 or AS02 is safe, elicits high titer antibody and induces IFN-gamma/IL-2 CD4+ T cells but does not protect against experimental Plasmodium falciparum infectionJames F Cummings, Michele D Spring, Robert J Schwenk, et al.
JAMA|May 19, 2025
Dexmedetomidine- or Clonidine-Based Sedation Compared With Propofol in Critically Ill Patients: The A2B Randomized Clinical TrialTimothy S Walsh, Richard A Parker, Leanne M Aitken, et al.
Thorax|October 10, 2014
Diagnostic accuracy of pulmonary host inflammatory mediators in the exclusion of ventilator-acquired pneumoniaThomas P Hellyer, Andrew Conway Morris, Daniel F McAuley, et al.
Neuro-Oncology|July 5, 2022
MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensusPeter M K de Blank, Andrea M Gross, Srivandana Akshintala, et al.
Neurology|December 14, 2016
Randomized placebo-controlled study of lovastatin in children with neurofibromatosis type 1Jonathan M Payne, Belinda Barton, Nicole J Ullrich, et al.
JAMA|December 9, 2024
Biomarker-Guided Antibiotic Duration for Hospitalized Patients With Suspected Sepsis: The ADAPT-Sepsis Randomized Clinical TrialPaul Dark, Anower Hossain, Daniel F McAuley, et al.
Journal of Medicinal Chemistry|May 31, 2002
3-Aminopyrrolidinone farnesyltransferase inhibitors: design of macrocyclic compounds with improved pharmacokinetics and excellent cell potencyIan M Bell, Steven N Gallicchio, Marc Abrams, et al.
American Journal of Respiratory and Critical Care Medicine|August 16, 2022
An Inhaled Galectin-3 Inhibitor in COVID-19 Pneumonitis: A Phase Ib/IIa Randomized Controlled Clinical Trial (DEFINE)Erin E Gaughan, Tom M Quinn, Andrew Mills, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|March 25, 2014
Development of a liver-targeted siRNA delivery platform with a broad therapeutic window utilizing biodegradable polypeptide-based polymer conjugatesStephanie E Barrett, Rob S Burke, Marc T Abrams, et al.
Pageof 130